Pazeqol 400mg Tablet

• Kidney cancer
  
• Soft tissue sarcoma
  

Every medicine has some side effects that manage on their own as your body gets used to the medicine, but some people may rarely experience severe side effects. In that case, the patient should contact the doctor immediately.

Some common side effects of Pazeqol 400mg Tablet include:

• High blood pressure
• Decreased appetite
• Weight loss
• Taste change
• Abnormal skin pigmentation
• Hair discoloration
• Tumor pain
• Breathlessness
• Headache
• Nausea
• Vomiting
• Musculoskeletal (bone, muscle or joint) pain
• Fatigue
• Change in color of hair
• Diarrhea

The Dosage of the tablet is usually decided by the doctor based on the health condition of the patient. Pazeqol 400mg Tablet should be taken on empty stomach at the same time every day. Take this drug as prescribed by the doctor. Swallow tablet as a whole with water and don't chew, break, or crush it.

• Pazeqol 400mg Tablet is an anti-cancer medication with active ingredient Pazopanib.
• It works by binding and inhibiting the enzyme receptors (tyrosine kinase) that are responsible for the proliferation of the cancerous cells.
• It also reduces the growth of new blood vessels within the tumor. This is how it works to slow down the progression of cancer.
  

• Van Der Graaf, W. T., Blay, J. Y., Chawla, S. P., Kim, D. W., Bui-Nguyen, B., Casali, P. G., ... & Hohenberger, P. (2012). Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet, 379(9829), 1879-1886.     
• Pick, A. M., & Nystrom, K. K. (2012). Pazopanib for the treatment of metastatic renal cell carcinoma. Clinical therapeutics, 34(3), 511-520.
• Schutz, F. A., Choueiri, T. K., & Sternberg, C. N. (2011). Pazopanib: Clinical development of a potent anti-angiogenic drug. Critical reviews in oncology/hematology, 77(3), 163-171.
• Miyamoto, S., Kakutani, S., Sato, Y., Hanashi, A., Kinoshita, Y., & Ishikawa, A. (2018). Drug review: pazopanib. Japanese Journal of Clinical Oncology, 48(6), 503-513.
• Sonpavde, G., & Hutson, T. E. (2007). Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Current oncology reports, 9(2), 115-119.                                                                                                                                               

​